176 related articles for article (PubMed ID: 6381006)
1. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy.
Chiasson JL; Ducros F; Poliquin-Hamet M; Lopez D; Lecavalier L; Hamet P
Diabetes Care; 1984; 7(4):331-7. PubMed ID: 6381006
[TBL] [Abstract][Full Text] [Related]
2. Effects of continuous subcutaneous insulin infusion versus multiple injections on insulin receptors in insulin-dependent diabetics.
Lecavalier L; Havrankova J; Hamet P; Chiasson JL
Diabetes Care; 1987; 10(3):300-5. PubMed ID: 3297578
[TBL] [Abstract][Full Text] [Related]
3. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes.
Alemzadeh R; Parton EA; Holzum MK
Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060
[TBL] [Abstract][Full Text] [Related]
5. Combined continuous subcutaneous insulin infusion and multiple subcutaneous injections in type I diabetic patients.
Schiffrin A; Belmonte M
Diabetes Care; 1981; 4(6):595-600. PubMed ID: 6751734
[TBL] [Abstract][Full Text] [Related]
6. Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences.
Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Aagenaes O; Mosand R
J Intern Med; 1990 Nov; 228(5):457-64. PubMed ID: 2254715
[TBL] [Abstract][Full Text] [Related]
7. Continuous basal insulin infusion without premeal boluses in insulin-dependent diabetes mellitus therapy.
Cimino A; Valentini U; Rotondi A; Candrina R; Salvi A; Spandrio S; Radaeli E; Giustina G
Acta Diabetol Lat; 1987; 24(3):193-8. PubMed ID: 3318256
[TBL] [Abstract][Full Text] [Related]
8. Improved insulin sensitivity in patients with type I diabetes mellitus after CSII.
Simonson DC; Tamborlane WV; Sherwin RS; Smith JD; DeFronzo RA
Diabetes; 1985 Aug; 34 Suppl 3():80-6. PubMed ID: 3894130
[TBL] [Abstract][Full Text] [Related]
9. Near-normoglycemia and late diabetic complications. The Oslo Study.
Dahl-Jørgensen K
Acta Endocrinol Suppl (Copenh); 1987; 284():1-38. PubMed ID: 3300128
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
[TBL] [Abstract][Full Text] [Related]
11. The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia.
Houtzagers CM; Visser AP; Berntzen PA; Heine RJ; van der Veen EA
Diabet Med; 1988 Mar; 5(2):135-8. PubMed ID: 2964978
[TBL] [Abstract][Full Text] [Related]
12. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
[TBL] [Abstract][Full Text] [Related]
13. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
[TBL] [Abstract][Full Text] [Related]
15. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
Catargi B; Breilh D; Roger P; Tabarin A
Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous insulin infusion in the treatment of juvenile-onset diabetes.
Buysschaert M; Lejeune M; Lambert AE
Diabete Metab; 1981 Sep; 7(3):189-93. PubMed ID: 7319116
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
Attia N; Jones TW; Holcombe J; Tamborlane WV
Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
[TBL] [Abstract][Full Text] [Related]
18. Metabolic response to fasting exercise in adolescent insulin-dependent diabetic subjects treated with continuous subcutaneous insulin infusion and intensive conventional therapy.
Schiffrin A; Parikh S; Marliss EB; Desrosiers MM
Diabetes Care; 1984; 7(3):255-60. PubMed ID: 6376018
[TBL] [Abstract][Full Text] [Related]
19. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
